Clinical Trial Update: A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ASP8232 for reducing central retinal thickness in diabetic macular edema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Diabetic Macular Edema

Drugs mentioned

• ASP8232 (ASP8232)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Diabetes Mellitus, Diabetic Macular Edema | Phase 2 | Status: COMPLETED